



IMMUNITRACK

Immuno-oncology has become one of the most promising and fastest growing areas of cancer research and drug development – do you have the best science to make the difference?


The **Immunitrack Neoscreen™** technology is applicable for developing various novel immunotherapeutic treatments against cancer:

- **Personalized cancer vaccine**
- **Chimeric Antigen Receptor (CAR) T-Cell therapy**
- **Mono- and Bi-specific antibody-based therapies**

The most successful immunotherapeutic treatments against cancer are the ones that elicit CD8+ and CD4+ T cell responses. Identifying cancer neo-epitopes, that can boost CD8+ and CD4+ T cell responses, is challenged by the poor performance of prediction software and high complexity of cellular based assays.

The **Immunitrack Neoscreen™** technology provides the best tools for identifying true cancer neo-epitopes and study both CD4+ and CD8+ T cells from cancer patients.

The **Immunitrack Neoscreen™** technology combines affinity and stability assays for accurate assessment of immunogenic epitopes.



Combination of affinity and stability assays for isolating epitopes that elicit CD4+ specific T cells

Affinity and stability analysis of CMV derived peptides. Most high affinity peptides (Kd<100nM) are relatively unstable. True T cell epitopes were confirmed by ELISPOT and MHC II Tetramer analysis are marked with red circles.



IMMUNITRACK

The Immunitrack Neoscreen™ technology offers:

- Reliable assessment of neo-epitope binding to MHC I & MHC II, reducing inaccuracies and false positives by combining affinity and stability assessment of MHC/neo-epitope.
- Unique capabilities for immunogenicity screening and robust reagents in the MHC II field – up to 80% of relevant neo-epitopes may be presented by MHCII (Nature. 2015 Jul 16;523(7560):370).
- Large and expanding portfolio of MHC I & II alleles for mouse and human.
- In vitro assay capabilities on thousands of neo-epitopes.
- Production capabilities of hundreds of biotinylated MHC/ neo-epitope complexes for T cell population studies.

Who we are

Immunitrack is an established scientific company, founded in Copenhagen, Denmark. It's a spin-out company from a world-leading

research groups within production and in-vitro analysis of MHC-peptide interactions, at University of Copenhagen. The molecules and assays have been validated in several multimillion dollar NIH and EU funded projects.

Key scientific contact



Sune Justesen (CSO)

Sune has a PhD in immunology from the University of Copenhagen. Sune devised a new method for producing functional MHC and perform MHC/peptide binding assays, that were used to develop

netMHC. This enabled his research laboratory at the University of Copenhagen, to become a global leader in that field, which ultimately secured large NIH grants as well as industrial collaborations. Sune has co-authored more than 20 papers related to MHC.

Interested? Let's get started!

The first 10 companies to contact us will get 10 peptides analysed **for free** with either one of the following MHCI (A*0201, A*0101, A*0301, C*0701 or C*0702) or MHCII (DRB1*0101, DRB1*0401 or DRB5*0101).

You are also welcome to contact us to get a non-binding quote and more information through our homepage.

www.immunitrack.com Phone: +45 6113 0072

Our technology has been featured in multiple peer-reviewed journals:

- Nat Nanotechnol. 2014 Aug;9(8):639-47.
- PLoS One. 2014 Apr 23;9(4):e94892.
- PLoS One. 2013 Sep 2;8(9):e73648.
- Small. 2013 Mar 11;9(5):666-72.
- Immunology. 2011 Apr;132(4):482-91.
- Immunome Res. 2010 Nov 13;6:9.
- PLoS One. 2010 May 7;5(5):e10533.
- Immunome Res. 2009 May 5;5:2.
- J Biomol Screen. 2009 Feb;14(2):173-80.
- PLoS Comput Biol. 2008 Jul 4;4(7):e1000107.
- PLoS One. 2008 Feb 27;3(2):e1678.
- PLoS One. 2007 Aug 29;2(8):e796.